Thursday, Oct 23, 2014

Sun Pharma settles Novartis lawsuit over leukemia drug

Sun Pharma is allowed to launch a generic version of Novartis' Gleevec in the US in 2016, under a settlement agreement between the two cos. (Reuters) Sun Pharma is allowed to launch a generic version of Novartis' Gleevec in the US in 2016, under a settlement agreement between the two cos. (Reuters)
Reuters | Mumbai | Posted: May 15, 2014 10:00 am

Sun Pharmaceutical Industries Ltd said it was allowed to launch a generic version of Novartis’ leukemia drug Gleevec in the United States on Feb. 1, 2016, under a settlement agreement between the two companies.

The other terms of the agreement are confidential, Sun Pharma said in a statement on Thursday.

Sun Pharma’s subsidiary holds a tentative approval from the U.S Food and Drug Administration for a generic version of Gleevec. As per IMS data, Gleevec had annual sales of about $2 billion in the United States, Sun said.

comments powered by Disqus
Featured ad: Discount Shopping
Follow

Get every new post delivered to your Inbox.

Join 1,289 other followers